[Alpha Biz= Reporter Kim Jisun] Huons has acquired the biopharmaceutical company Paenjen, moving into biopharmaceutical research and development (R&D) and expanding its contract development and manufacturing organization (CDMO) business.
On November 5, Huons announced an investment of KRW 14.3 billion to acquire 2,647,378 shares of Paenjen. The acquisition involves purchasing existing shares and participating in a third-party share issuance. Through this transaction, Huons has secured a total of 3,983,167 shares, amounting to a 31.53% stake, making it the largest shareholder.
Following the completion of the share acquisition, Huons plans to gain management control of Paenjen through an extraordinary shareholders' meeting, incorporating Paenjen as a subsidiary.
With this acquisition, Huons aims to strengthen its biopharmaceutical R&D and CDMO capabilities. Paenjen has GMP-certified facilities for biopharmaceutical production and proprietary cell line development technology, known as "Paenjen CHO-TECH."
Earlier, in June, Paenjen signed a contract with Huons Lab, a subsidiary of Huons Global, to produce clinical samples and validate human-derived hyaluronidase, marking a strategic step in Huons' expansion in the biopharmaceutical sector.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
